Enbrel, Remicade Anti-TNF Class Labeling Debated By FDA Advisory Cmte.

Anti-TNF rheumatoid arthritis drug class labeling for tuberculosis risk was discussed by FDA's Arthritis Advisory Committee during an Aug. 17 safety update on Immunex' Enbrel (etanercept) and Centocor's Remicade (infliximab).